RIP4 Antibody



Orders: 877-616-CELL (2355)

orders@cellsignal.com

877-678-TECH (8324) Support:

Web: info@cellsignal.com

cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only Not for Use in Diagnostic Procedures

Applications: WB, IP	Reactivity: H	Sensitivity: Endogenous	MW (kDa): 86	Source: Rabbit	UniProt ID: #P57078	Entrez-Gene Id 54101	
Product Usage Information	Application			Dilution			
	Western Blotting			1:1000			
	lmi	Immunoprecipitation			1:50		
Storage		Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 μ g/ml BSA and 50% glycerol. Store at – 20°C. Do not aliquot the antibody.					
Specificity / Sensit	ivity RIP	RIP4 Antibody recognizes endogenous levels of total RIP4 protein.					
Species predicted react based on 100		Monkey					

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human RIP4 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

The receptor-interacting protein (RIP) family of serine-threonine kinases (RIP, RIP2, RIP3, and RIP4) are important regulators of cellular stress that trigger pro-survival and inflammatory responses through the activation of NF-kB, as well as pro-apoptotic pathways (1). In addition to the kinase domain, RIP contains a death domain responsible for interaction with the death domain receptor Fas and recruitment to TNF-R1 through interaction with TRADD (2,3). RIP-deficient cells show a failure in TNF-mediated NF-kB activation, making the cells more sensitive to apoptosis (4,5). RIP also interacts with TNF-receptor-associated factors (TRAFs) and can recruit IKKs to the TNF-R1 signaling complex via interaction with NEMO, leading to IKB phosphorylation and degradation (6,7). Overexpression of RIP induces both NF-kB activation and apoptosis (2,3). Caspase-8-dependent cleavage of the RIP death domain can trigger the apoptotic activity of RIP (8).

Receptor-interacting serine-threonine kinase 4 (RIP4, ANKRD3, DIK, PKK, or RIPK4) is a membraneassociated, ankyrin repeat-containing member of the RIP family first identified in HaCat cells (9,10). RIP4 has been shown to be involved in keratinocyte differentiation in vivo as well as wound repair (11-13). Studies indicate that siRNA knockdown of RIP4 in human xenografted tumor cells suppresses Wntdependent growth while over-expression of RIP4 in vitro stabilized β-catenin and lead to an increase in Wnt-dependent gene expression (14).

Background References

- 1. Meylan, E. and Tschopp, J. (2005) Trends Biochem Sci 30, 151-9.
- 2. Hsu, H. et al. (1996) Immunity 4, 387-96.
- 3. Stanger, B.Z. et al. (1995) Cell 81, 513-23.
- 4. Ting, A.T. et al. (1996) EMBO J 15, 6189-96.
- 5. Kelliher, M.A. et al. (1998) Immunity 8, 297-303.
- 6. Devin, A. et al. (2000) Immunity 12, 419-29.
- 7. Zhang, S.Q. et al. (2000) Immunity 12, 301-11.
- 8. Lin, Y. et al. (1999) Genes Dev 13, 2514-26.
- 9. Bhr, C. et al. (2000) J Biol Chem 275, 36350-7.
- 10. Chen, L. et al. (2001) J Biol Chem 276, 21737-44.
- 11. Rountree, R.B. et al. (2010) J Invest Dermatol 130, 102-12. 12. Adams, S. et al. (2007) J Invest Dermatol 127, 538-44.
- 13. Holland, P. et al. (2002) Curr Biol 12, 1424-8.
- 14. Huang, X. et al. (2013) Science 339, 1441-5.

3/23/24. 1:12 PM

Species Reactivity

RIP4 Antibody (#12636) Datasheet Without Images Cell Signaling Technology Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key
Cross-Reactivity Key

WB: Western Blotting IP: Immunoprecipitation

H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse

GP: Guinea Pig Rab: rabbit All: all species expected

Trademarks and Patents

Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.

Limited Uses

Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.